Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Affibody AB is currently managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area, with 1 pending office action on the docket. This prosecution is being handled by 1 distinct examiner and is situated within 1 distinct art unit. This indicates a highly focused set of active matters, likely centered on a specific biological or pharmaceutical innovation.
The busiest examiner for Affibody AB is VARADARAJ, ARCHANA, who is currently overseeing 1 busiest examiner pending office action. As the sole examiner currently reviewing the company's pending applications, their individual perspective and application of patent law in the Biotechnology & Pharmaceuticals sector are critical. The concentration of the portfolio's active workload under 1 distinct examiner allows for a consistent approach but also increases the impact of that examiner's specific requirements.
In the complex Biotechnology & Pharmaceuticals field, practitioners must be prepared for the rigorous standards of the 1 distinct art unit. With only 1 pending office action, the successful resolution of this matter is the primary focus for the portfolio's current growth. A thorough understanding of the past actions of VARADARAJ, ARCHANA and the technical expectations of the art unit will be key to achieving a positive outcome for the pending claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264884 | NEW HER2-BINDING POLYPEPTIDE | VARADARAJ, ARCHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264884 | NEW HER2-BINDING POLYPEPTIDE | VARADARAJ, ARCHANA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264884 | NEW HER2-BINDING POLYPEPTIDE | VARADARAJ, ARCHANA | 1658 | §103DP | Final Rejection | — | Pending | Aug 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAffibody AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Archana Varadaraj has the most, with 1 of Affibody AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
